Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Innate Pharma S-A stock | $3.91

Learn how to easily invest in Innate Pharma S-A stock.

Innate Pharma S.A
NASDAQ: IPHA - USD
BIOTECHNOLOGY
$3.32
+$0.04 (+1.22%)

Innate Pharma S.A is a biotechnology business based in the US. Innate Pharma S-A shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma S-A employs 244 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Innate Pharma S-A

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IPHA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Innate Pharma S-A stock price (NASDAQ: IPHA)

Use our graph to track the performance of IPHA stocks over time.

Innate Pharma S-A shares at a glance

Information last updated 2021-07-31.
Latest market close$3.91
52-week range$3.04 - $6.65
50-day moving average $3.45
200-day moving average $4.07
Wall St. target price$7.19
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Innate Pharma S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Innate Pharma S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Innate Pharma S-A price performance over time

Historical closes compared with the close of $3.91 from 2021-05-28

1 week (2021-07-21) N/A
1 month (2021-07-01) 9.83%
3 months (2021-04-30) -7.78%
6 months (2021-01-28) N/A
1 year (2020-07-28) N/A
2 years (2019-07-28) N/A
3 years (2018-07-28) N/A
5 years (2016-07-28) N/A

Is Innate Pharma S-A under- or over-valued?

Valuing Innate Pharma S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innate Pharma S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innate Pharma S-A's EBITDA

Innate Pharma S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.3 million.

The EBITDA is a measure of a Innate Pharma S-A's overall financial performance and is widely used to measure a its profitability.

Innate Pharma S-A financials

Revenue TTM $70.5 million
Gross profit TTM $11.8 million
Return on assets TTM -3.27%
Return on equity TTM -34.27%
Profit margin -90.82%
Book value $1.98
Market capitalisation $262.4 million

TTM: trailing 12 months

Shorting Innate Pharma S-A shares

There are currently 12,792 Innate Pharma S-A shares held short by investors – that's known as Innate Pharma S-A's "short interest". This figure is 98.8% up from 6,435 last month.

There are a few different ways that this level of interest in shorting Innate Pharma S-A shares can be evaluated.

Innate Pharma S-A's "short interest ratio" (SIR)

Innate Pharma S-A's "short interest ratio" (SIR) is the quantity of Innate Pharma S-A shares currently shorted divided by the average quantity of Innate Pharma S-A shares traded daily (recently around 31980). Innate Pharma S-A's SIR currently stands at 0.4. In other words for every 100,000 Innate Pharma S-A shares traded daily on the market, roughly 400 shares are currently held short.

However Innate Pharma S-A's short interest can also be evaluated against the total number of Innate Pharma S-A shares, or, against the total number of tradable Innate Pharma S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innate Pharma S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Innate Pharma S-A shares in existence, roughly 0 shares are currently held short) or 0.0003% of the tradable shares (for every 100,000 tradable Innate Pharma S-A shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Innate Pharma S-A.

Find out more about how you can short Innate Pharma S-A stock.

Innate Pharma S-A share dividends

We're not expecting Innate Pharma S-A to pay a dividend over the next 12 months.

Innate Pharma S-A share price volatility

Over the last 12 months, Innate Pharma S-A's shares have ranged in value from as little as $3.04 up to $6.65. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma S-A's is 0.121. This would suggest that Innate Pharma S-A's shares are less volatile than average (for this exchange).

Innate Pharma S-A overview

Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S. A.

Frequently asked questions

What percentage of Innate Pharma S-A is owned by insiders or institutions?
Currently 1.55% of Innate Pharma S-A shares are held by insiders and 0.378% by institutions.
How many people work for Innate Pharma S-A?
Latest data suggests 244 work at Innate Pharma S-A.
When does the fiscal year end for Innate Pharma S-A?
Innate Pharma S-A's fiscal year ends in December.
Where is Innate Pharma S-A based?
Innate Pharma S-A's address is: 117, Avenue de Luminy, Marseille, France, 13009
What is Innate Pharma S-A's ISIN number?
Innate Pharma S-A's international securities identification number is: US45781K2042
What is Innate Pharma S-A's CUSIP number?
Innate Pharma S-A's Committee on Uniform Securities Identification Procedures number is: 45781K204

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site